Growth factors are defined as small proteins that trigger a cellular response after binding to cell receptors; Tissue engineering is now clinically applicable in a commercially available system involving the use of recombinant human platelet-derived growth factor. The objective of this study is to evaluate clinical and radiographic parameters in bone defects treated with platelet-derived growth factor in combination with allograft. Our hypothesis: Defects treated with DFDBA and rhPDGF-BB have better clinically and radiographic results that the defects treated with DFDBA and saline solution.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Probing depth
Timeframe: Initial and six months after surgery
Bleeding on probing
Timeframe: Initial and six months after surgery
Gingival Recession
Timeframe: Initial and six months after surgery
Clinical Attachment Level
Timeframe: Initial and six months after surgery
Gingival Phenotype
Timeframe: Initial and six months after surgery
Plaque control record
Timeframe: Initial and six months after surgery
Radiographic Measurements
Timeframe: Initial and six months after surgery